advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa
Company profile
Ticker
NRSN, NRSNW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NRSN stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
22 Feb 24
6-K
Report of Foreign Private Issuer
7 Feb 24
6-K
Report of Foreign Private Issuer
9 Jan 24
6-K
Report of Foreign Private Issuer
9 Jan 24
424B3
Prospectus supplement
27 Dec 23
6-K
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
27 Dec 23
6-K
Report of Foreign Private Issuer
21 Dec 23
424B3
Prospectus supplement
14 Dec 23
6-K
Report of Foreign Private Issuer
14 Dec 23
424B3
Prospectus supplement
5 Dec 23
Latest ownership filings
SC 13G/A
Gordon Ariel
13 Feb 24
SC 13G/A
Ben-Noon Alon
13 Feb 24
SC 13G/A
Ben-Noon Alon
5 Apr 23
SC 13G/A
Gordon Ariel
15 Mar 23
SC 13G/A
E Europe Ltd
15 Mar 23
SC 13G
Real Property International Ltd
15 Mar 23
SC 13G
E Europe Ltd
30 Dec 21
SC 13G
Ben-Noon Alon
23 Dec 21
SC 13G
Gordon Ariel
20 Dec 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
16.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 7 |
Closed positions | 0 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 2.24 bn |
Total shares | 2.19 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 1.27 mm | $1.89 bn |
Real Property International | 452.50 k | $1.23 mm |
Point72 Asset Management | 100.00 k | $149.00 mm |
Meitav Dash Investments | 95.00 k | $141.55 mm |
Hudson Bay Capital Management | 87.73 k | $20.73 mm |
Warberg Asset Management | 77.71 k | $15.39 mm |
Clear Street | 58.67 k | $14.00 k |
Citadel Advisors | 37.93 k | $8.96 mm |
JustInvest | 11.19 k | $16.68 mm |
JPM JPMorgan Chase & Co. | 1.30 k | $1.90 mm |
Press releases
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
21 Feb 24
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
7 Feb 24
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
30 Jan 24
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
9 Jan 24